Compounds of the structure (I) are described, wherein R1-R6, R11, R12, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a varie…
Compounds of the following structure are provided, wherein n, R1-R3 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, d…
Compounds of the following structure are provided, wherein R1-R4 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysf…
Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a var…
Compounds of the following structure are described (I), wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a…
The use of compounds of formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhe…
The use of compounds of formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhe…
The use of compounds of formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhe…
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, formula II, or tautomers thereof, in a regimen which involves delivering one or more of…
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula (I), or tautomers thereof, in a regimen which involves delivering one or more of a selecti…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I or formula II, or tautomers thereof, in a regimen which involves delivering one or more …
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which involves delivering one or more of a selective…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single sub…
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, formula II, or tautomers thereof, in a regimen which involves delivering one or more of…
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula (I), or tautomers thereof, in a regimen which involves delivering one or more of a selecti…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the general structure: wherein: R1, and R2 are chosen indep…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein R1 and R2 may be single substitu…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having general structure (I) wherein: R1, and R2 are chosen independen…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (I): wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing, in combination with progestins, estrogens, or both, substituted indoline derivative compounds which are antagonists of the progesterone receptor having general s…
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
This invention relates to cyclic combination therapies utilizing, in combination with progestins, estrogens, or both, compounds which are progesterone receptor antagonists of general structure: (I) wherein: R1 and R2 are H, CORA, or NRBCORA…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (1), wherein R1 and R2 may be single substit…